. Platelet-derived growth factor-BB enhances MSC-mediated cardioprotection via suppression of miR-320 expression.
heart function after ischemic injury (17, 18, 33, 50) . However, many clinical trials have shown that the cardioprotective effects of MSC therapy are modest and of limited duration, in part due to low rates of engraftment, transdifferentiation, cell fusion, and survival (14, 23, 30, 36, 48) . Moreover, inflammatory molecules, proapoptotic factors, and a hypoxic environment in the ischemic heart also have detrimental effects on these implanted cells. Accordingly, a number of strategies have been attempted to improve the therapeutic efficacy of MSCs, including improving their in vivo survival rate, ability to promote angiogenesis, homing to the heart, and augmentation of MSC paracrine signaling.
One promising agent for enhancing MSC paracrine function and cardioprotection is platelet-derived growth factor (PDGF)-BB. PDGF is a potent mitogen of cells of mesenchymal origin, including MSCs (38) and is synthesized, stored, and released by many differentiated cell types, such as platelets (8) , endothelial cells (7) , smooth muscle cells (53) , fibroblasts (10) , and monocytes (34) . PDGF is a dimeric glycoprotein composed of two A chains (-AA), two B chains (-BB), or an A/B heterodimer (-AB). Two types of the PDGF receptor (PDGFR) have been identified: PDGFR␣ and PDGFR␤ (32) , and both subtypes are capable of binding PDGF. Upon activation by PDGF, the receptor subunits dimerize and subsequently activate numerous signal transduction pathways, including JNK/ c-Jun, PKC, ERK, JAK/STATs, and PI3K/Akt, which play profound roles in regulating cell growth, proliferation, and differentiation (9, 27, 40, 42) .
PDGF has also been shown to alter MSC microRNA (miRNA) expression (19) . miRNAs are small noncoding RNAs that function in transcriptional and posttranscriptional regulation of gene expression (6) via mRNA cleavage, translational repression and polyadenylation (mRNA degradation by removal of its 3=-poly-A tail) (49) . miRNA genes can be found in the introns of protein-coding genes and in both introns and exons of noncoding RNAs (41) . Expression of miRNAs is regulated in a spatial, temporal, and physiological manner and may require different mechanism of biogenesis, according to their genomic location (e.g., extronic, intronic, etc.) (41) .
The present study focused on assessing the therapeutic efficacy of PDGF-preconditioned MSCs and also on the role of c-Jun, a well-known activator protein-1 (AP-1) transcription factor that is activated by PDGF, in regulating the expression of miRNAs that may modulate MSC paracrine signaling. We hypothesized that PDGF improved MSC-derived cardioprotec-tion via modulating the expression of cytoprotective paracrine factors and miRNAs. By using an isolated mouse ischemic/ reperfusion model, we tested the role of PDGF and hsa-miR320b whose expression level was suppressed by PDGF. Our investigation provides insight into the intracellular mechanisms that underlie the therapeutic potential of MSCs by demonstrating new ways to "prime" these cells for improved therapeutic application.
MATERIALS AND METHODS
Reagents. PDGF was obtained from Becton-Dickenson (Franklin Lakes, NJ). All other chemicals were obtained from Sigma (St. Louis, MO).
Human MSC culture. MSCs (purchased from Lonza, Walkersville, MD) were tested for purity by flow cytometry and for their ability to differentiate into osteogenic, chondrogenic, and adipogenic lineages (35) . MSC purity was validated by positivity for CD105, CD166, CD29, and CD44 and negativity for CD14, CD34, and CD45 (3). MSCs were thawed, and the culture was process initiated, according to the manufacturer's instructions, by plating in tissue culture flasks (Corning, Corning, NY) containing MSC growth medium (Lonza) at 37°C in 5% CO2-90% humidity. The medium was changed every 3 days. After cells attained 70% confluence, MSCs were transferred to 6-or 12-well plates (Corning) at 5 ϫ 10 4 cells·well Ϫ1 ·ml Ϫ1 for experimentation. Isolated mouse heart perfusion (Langendorff). Hearts were isolated as previously described (25) . Mice were anesthetized (sodium pentobarbital, 60 mg/kg ip) and heparinized (500 U ip), and the hearts were then rapidly excised via median sternotomy and placed in 4°C modified Krebs-Henseleit (KH) solution containing the following (in mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 0.5 EDTA, 25 NaHCO3, 1.2 KHPO4, 1.2 MgSO4, 2 Na pyruvate, 10 HEPES, and 11 dextrose. For all of our isolated perfusion heart experiments, the hearts were excised very rapidly and then cannulated in Ͻ1 min to minimize the possibility of ischemic preconditioning. The aorta was cannulated, and the heart was perfused under constant pressure (75 mmHg) using a modified KH solution at 37°C and bubbled with 95% O2. A pulmonary arteriotomy was performed to allow free drainage of coronary sinus effluent, as was a left atriotomy to allow insertion of a waterfilled latex balloon into the left ventricle. The balloon pressure was adjusted to a mean left ventricular end-diastolic pressure (EDP) of 10 mmHg (range, 6 -16 mmHg) during equilibration. Hearts were allowed to equilibrate for 15 min before vehicle or MSC infusion and were paced at 420 beats/min to ensure a standard heart rate between groups. MSCs (5 ϫ 10 4 ) were washed with phosphate-buffered saline, resuspended in 1.0 ml warm (37°C), oxygenated modified KH solution, and then infused into the coronary arteries 1 min immediately before ischemia. A three-way stopcock above the aortic root was used to create global ischemia, during which the heart was placed in a 37°C degassed organ bath for 25 min. Hearts were then reperfused for 40 min after ischemia. The left ventricular pressure (LVP) and EDP were continuously recorded using a PowerLab 8 preamplifier/digitizer (AD Instruments, Milford, MA) interfaced with a Dell PC. The left ventricular developed pressure (LVDP) and the maximum positive and negative values of the first derivative of pressure (ϩdP/dt and ϪdP/dt) were calculated using PowerLab software.
Transfection of miRNA mimics. hsa-miR-320b mimic and mirVana miRNA nonspecific control were obtained from Life Technologies (Carlsbad, CA). MSCs from the same starting cell isolation were transfected with both hsa-miR-320b or negative control miRNA at a concentration of 30 nM, using Lipofectamine 2000 (Invitrogen, CA), per the manufacturer's instructions. Briefly, 24 h before miRNA transfection, cells were plated in 12-well plates at 5 ϫ 10 4 cells·well Ϫ1 ·ml Ϫ1 . On culture day 2, the lipofectamine-miRNA complex was added. After 1 day of transfection (day 3 in culture), the lipofectamine-siRNA complex was washed out, and MSC growth culture medium with or without PDGF (10 ng/ml) was added to the cells and allowed to incubate for an additional 2 days. Three days after transfection (day 5 in culture), the dish culture (conditioned) media were collected for ELISA and cytokine array analysis. Cells were also lysed and cell extracts were prepared for Western blot and kinase array assays.
TaqMan miRNA analysis. MSCs were plated at 1 ϫ 10 5 cells per well in six-well plates. After 24 h, cells were stimulated by 10 ng/ml PDGF for 48 h. MSC total miRNA was then isolated and enriched using a mirVana miRNA isolation kit (Life Technologies). TaqMan miRNA assays were performed by the manufacturer's protocol, as previously described (20) . Briefly, the expression of mature hsa-miR320b (Life Technologies Assay ID: MC13132), hsa-miR-23b (Assay ID:000400), hsa-miR-27b (Assay ID:000409), and hsa-miR-16-2 (Assay ID: 002171) was examined in control human MSCs and PDGFtreated MSCs. Each sample was analyzed in triplicate. Ten nanograms of enriched small RNA were then converted into cDNA using specific miRNA primers (supplied with the TaqMan miRNA assays), using a TaqMan MicroRNA Reverse Transcription Kit (Life Technologies). Real-time PCR was performed using standard Taqman MicroRNA Assay Protocols on a 7500 Real-Time PCR System (Life Technologies). The Taqman MicroRNA Assay for RNU44 (Assay ID:001094) was used to normalize the relative abundance of specific miRNA.
ELISA. MSCs (5 ϫ 10 4 ) were plated in 12-well plates overnight and then treated with PDGF at different concentrations. Supernatants from each MSC group were then collected and assayed for angiogenic factor production using a commercially available ELISA kit (R&D Systems, Minneapolis, MN). All samples and standards were measured in duplicate. The absorbance of the samples was determined with a standard microplate (ELISA) reader at 450 nm, with a reference wavelength of 540 nm.
Angiogenesis array assay. MSCs (1 ϫ 10 5 ) were plated in six-well plates overnight and then transfected with hsa-miR-320b mimic or its mirVana miRNA mimic negative control at 30 nM final concentration. Twenty-four hours after transfection, cells were stimulated by 10 ng/ml PDGF for another 48 h. Cell supernatants were collected and assayed for angiogenic factor production, per the manufacturer's (R&D Systems) protocol. Briefly, the array membranes immobilized with capture antibodies were incubated with 1 ml of conditioned media and the membranes were then incubated with a biotin-conjugated detection antibody cocktail. After being washed, the membranes were then incubated with horseradish-conjugated streptavidin and the signals detected using SuperSignal West Pico stable peroxide solution (Pierce, Rockford, IL). Signal densities were compared using National Institutes of Health (NIH) ImageJ software.
Protein isolation and Western blot analysis. Western blot analysis was performed to measure the activation (phosphorylation) of Akt, ERK, and STAT3. Cell extracts were prepared by direct lysis of cells in cold RIPA buffer (Sigma) containing a protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma). Lysates were then centrifuged at 10,000 g for 10 min, and the supernatants were assayed for total protein concentration. Cell lysate protein (10 g/lane) was then electrophoresed on 4 -12% bis Tris gels (Life Technologies) and transferred to nitrocellulose membranes. The membranes were blocked in 5% dry milk for 1 h and then incubated with primary antibodies for phospho(P)-Akt, total (T) T-Akt, P-ERK, T-ERK, P-c-Jun, and T-c-Jun (Cell Signaling Technology, Boston, MA), followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody and detection using SuperSignal West Pico stable peroxide solution (Pierce) . Actin levels were measured to ensure equal loading of protein. Band densities were compared using NIH ImageJ software.
Human phospho-kinase antibody array assay. Phospho-kinase activity was measured using a commercially available kinase array kit (R&D Systems). Briefly, cell lysates isolated from each MSC group were diluted and mixed with a cocktail of biotinylated detection antibodies. The cell lysate/detection antibody mixtures were then incubated with nitrocellulose membranes spotted with capture antibodies. Protein/detection antibody/capture antibody complexes were then detected by adding horseradish-conjugated streptavidin and SuperSignal West Pico stable peroxide solution to the membranes (Pierce) . Signal densities were measured and compared using NIH ImageJ software.
Predicting AP-1 binding sites in miRNA promoters. Genomic loci for the promoter regions of human miRNAs were acquired using MpromDB, a curated database that documents the annotations of gene promoters derived from ChIP-seq datasets from either RNA polymerase II or histone marks (21) . The promoter sequences were further retrieved from the human reference genome (build hg18), based on the promoter regions acquired using MpromDB. AP-1 binding sites within the miRNA promoter regions were predicted based on the position specific scoring matrix (PSSM) of AP-1 binding proteins, as documented in the TRANSFAC database. Matching scores were then calculated for each genomic locus, as described previously (31) . A specific genomic locus was considered to be a candidate AP-1 binding site if its matching score was greater than a cutoff score, determined as the top 1% of loci that were evaluated.
Data analysis. All values were reported as means Ϯ SE. LVDP, Ϯdp/dt, and EDP values were presented as a percentages of baseline. Statistical differences between the control groups and those obtained under various treatment conditions were determined using a Student's t-test, one-way, or two-way ANOVA, followed by a Tukey post hoc analysis. Values of P Ͻ 0.05 were judged to be statistically significant.
RESULTS

PDGF increases MSC VEGF production in a dose-dependent manner and rapidly activates intracellular signaling cascades. MSCs (5 ϫ 10
4 ) were plated in 12-well plates overnight and then treated with PDGF at different concentrations (0 -100 ng/ml) for 24 h. The supernatants were then collected and measured for VEGF production. As shown in Fig. 1A , PDGF treatment increased VEGF expression in a dose-dependent manner. Based on these results, we chose 10 ng/ml, the minimum dose provoking maximum VEGF release, as a standard treatment dose for our later experiments.
We further examined the mechanism by which PDGF may stimulate MSCs to produce VEGF and other cytoprotective paracrine factors. The cells were stimulated with PDGF (10 ng/ml) for 30 min and then exposed to lysis buffer. Activation of intracellular signaling cascades and transcription factors was examined using a Human Phospho-Kinase Antibody Array Assay Kit (see MATERIALS AND METHODS for details). As shown in Fig. 1B , PDGF increased phosphorylated ERK, JNK, Akt, CREB, and ␤-catenin after 30 min of treatment.
We also examined the activation of c-Jun, a JNK-dependent transcription factor, following PDGF treatment. As shown in Fig. 1C , c-Jun phosphorylation levels were significantly increased 10 min after PDGF treatment. Interestingly, c-Jun and p-c-Jun were strongly detected in the nucleus but not in the cytosol (Fig. 1C) .
To investigate whether PDGF progressively activates intracellular signaling molecules, we next examined its time-dependent activation of ERK and Akt. As shown in Fig. 1D , PDGF increased phosphorylation of both ERK and Akt after 5 min. Interestingly, phosphorylation levels of both signaling molecules decreased 24-h after stimulation. human mesenchymal stem cells were plated in 12-well plates (5 ϫ 10 4 cell/well) for 24 h and stimulated by PDGF (10 ng/ml) for another 24 h. Supernatants were collected and the total amounts of VEGF measured. Results are means Ϯ SE; n ϭ 3/group. *P Ͻ 0.05 vs. naïve mesenchymal stem cell (MSC) control. B-D: cells were stimulated with PDGF (10 ng/ml) and total cell lysates, cytosolic protein, and nuclear protein collected at different time points. The activation of intracellular kinases was measured by protein kinase arrays (B) and Western blots (C and D). C, control; P, PDGF (10 ng/ml) for 10 min; TBP, TATA-binding protein, nuclear protein control.
PDGF improves MSC-mediated cardioprotection following ischemic injury.
To examine whether PDGF improved MSCmediated cardioprotection, a standard ex vivo Langendorff mouse heart model was used. MSCs were treated with 10 ng/ml PDGF for 48 -54 h before collection for experiments. Concurrently, isolated mouse hearts were randomized into three groups that were allowed to equilibrate for 15 min, followed by coronary artery infusion with vehicle, naïve MSCs, or PDGF-pretreated MSCs (5 ϫ 10 4 ), immediately before ischemia. Hearts were then reperfused for 40 min, and the LVP was monitored constantly. Several indexes of left ventricular performance, namely, LVDP, EDP (indicating the compliance of ventricular muscle), maximum ϩdP/dt, and ϪdP/dt were obtained by analyzing LVP data. Figure 2 , A-C, shows representative recording traces of LVP of isolated mouse hearts infused with vehicle, naïve human MSCs, and PDGF-pretreated MSCs. Both naïve and PDGFpretreated MSCs infused into coronary circulation immediately before global ischemia improved heart functional recovery during the 40-min reperfusion period. The isolated mouse hearts that received PDGF-treated MSCs showed better functional recovery, compared with the naïve MSC group. This was demonstrated via improved LVDP, ϩdp/dt, and ϪdP/dt in the experimental groups (naïve and/or PDGF-treated MSCs), compared with the vehicle controls (Fig. 2, D-F) . However, EDPs were not different between any of the groups (Fig. 2G) , which may suggest the equivalence of injury after ischemia-reperfusion.
PDGF modulates the expression of c-Jun target miRNAs. We next tested MSC expression of hsa-mIRs-16-2, -23b, -27b, and -320b, predicted c-Jun target genes due to their promoter regions possessing predicted c-Jun binding sites greater than a selected threshold. MSCs (1 ϫ 10 5 /2-ml/well) were plated in six-well plates and treated with 10 ng/ml PDGF for 48 h. Total RNA extracts were enriched for small RNA species, and the expression of the aforementioned miRNAs was examined using standard TaqMan assays. Following PDGF treatment, MSC expression of hsa-miR-16-2 was significantly higher than in the vehicle control; in contrast, expression levels of hsa-miR-23b, hsa-miR-27b, and hsa-miR-320b were lower (Fig. 3) .
Overexpression of hsa-miR-320b abolishes enhanced MSCmediated cardioprotection. Previously, it was shown that mouse cardiomyocytes release exosomal miR-320 for possible uptake by mouse cardiac endothelial cells (51) . Based on that study, and our findings described above, we focused on determining the role of hsa-miR-320b in MSC-mediated cardioprotection and paracrine signaling. Consequently, an hsa-miR320b mimic was transfected into human MSCs, and successful , ϩdp/dt and Ϫdp/dt (ventricular contractility assessment), and end-diastolic pressure (EDP). Eq, equilibrium; Is, ischemia; Re, reperfusion. Results are means Ϯ SE; n ϭ 5/group. *P Ͻ 0.05 vs. vehicle control; #P Ͻ 0.05 vs. naïve MSCs, as determined using two-way ANOVA followed by Bonferroni's post-hoc analysis. transfection confirmed by TaqMan miRNA RT-PCR. the hsamiR-320b mimic at 30 nM was chosen for later experiments because it was the minimum concentration that induced maximum miR-320b expression levels (Fig. 4A) .
MSCs were then plated in 1 ϫ 10 5 /2-ml/well in six-well plates overnight and then transfected either with 30 nM miR320b mimic or nonspecific control miRNA. Twenty-four hours after transfection, the cells were then treated with 10 ng/ml PDGF for 48 -56 h. Cells (5 ϫ 10 4 ) were then collected and infused into the coronary circulation of isolated mouse hearts. The isolated mouse hearts were randomly divided into two groups: 1) MSCs ϩ PDGF ϩ control miR; and 2) MSCs ϩ PDGF ϩ miR-320b mimic. Figure 4 , B and C, demonstrates a representative LVP recording trace of both groups; as shown, the hearts receiving PDGF-treated, control miR-transfected MSCs demonstrated similar functional recovery, compared with the naïve MSCϩPDGF group (Figs. 2 and 4) . In contrast, the hearts receiving miR-320b-overexpressing MSCs showed less MSC-derived protection and functional recovery, compared with control miR-transfected MSCs, as demonstrated by decreased LVDP, ϩdp/dt, and Ϫdp/dt (Fig. 4 D-F) . EDPs, however, did not show any significant differences between groups (Fig. 4G) .
Overexpression of miR-320 alters MSC paracrine properties. We further invested whether overexpression of miR-320 altered MSC paracrine signaling. The expression of paracrine factors was examined by using a human angiogenic growth factor array. The basal expression of insulin-like growth factorbinding proteins (IGFBP)-1, -2, and -3 was significantly increased after miR-320 overexpression. Additionally, PDGF treatment further increased IGFBP-1, -2, and -3 secretion (Fig.  5A) . Overexpression of miR-320, alone, did not change basal or PDGF-stimulated VEGF or stromal cell-derived factor-1 (SDF-1) expression, although exogenously added PDGF did increase VEGF secretion from MSCs either transfected with nonspecific control miRNA or miR-320. We also confirmed this observation using ELISA (Fig. 5B) . Interestingly, the mRNA levels of both factors (VEGF and SDF-1) were not changed at 48 h after PDGF stimulation (Fig. 5B) . Both PDGF and miR-320 overexpression increased tissue inhibitor of matrix metalloproteinase (TIMP-1) expression and the rate of cell proliferation (Fig. 5B) . The expression levels of other growth factors (as measured by signal densities) are listed in Table 1 .
DISCUSSION
In this study, we demonstrated that 1) PDGF increased MSC VEGF production in a dose-dependent manner; 2) PDGF (10 ng/ml) rapidly (Ͻ30 min) activated multiple intracellular signaling factors and transcription factors, including JNK/c-JUN, ERK, Akt, CREB, and ␤-catenin; 3) PDGF inhibited p38␣ activity; 4) PDGF stimulated intracellular signaling pathways in a spatial and temporal manner; 5) the primary cellular location of c-Jun, in both its activated and quiescent forms, is in the nucleus; 6) 48-h PDGF pretreatment of human MSCs improved MSC-mediated cardioprotection in an ischemic-reperfused, isolated mouse heart model; 6) PDGF regulated the expression of c-Jun-targeted miRNAs, namely miR-16-2, -23b, -27b, and -320b; 7) transfection of miR-320b mimic attenuated the cardioprotective effect of PDGF-pretreated MSCs; 8) transfection of miR-320b mimic increased the expression levels of IGFBP-1, -2, -3, and TIMP-1; and 9) PDGF increased the expression of SDF-1 and VEGF in cells, with or without miR-320 transfection.
Both allogeneic and autologous MSCs have been reported to favorably affect patient functional capacity, quality of life, and ventricular remodeling (13, 14, 22) . MSCs protect ischemic myocardium via secretion of a cascade of factors with cytoprotective potential. Due to the short experimental period (Ͻ2 h), it is unlikely neovascularization would occur during the process. However, we observed that MSCs released angiogenic growth factors, cytokines, and chemokines that can induce the formation of new blood vessels in an in vivo setting. These factors include vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin growth factor 1 (IGF-1), the chemokines KC (keratinocyte chemoattractant) and monocyte chemoattractant protein-1(MCP-1), and many others (50, 52) . The newly formed capillaries should increase blood perfusion of the injured myocardium and improve wound healing.
Besides inducing angiogenesis, MSCs also released paracrine factors that suppressed the inflammatory response of injured tissue, decreasing fibrosis and stimulating the activity of endogenous endothelial progenitor cells (12) . Such secretory effects help to preserve heart tissue, decrease cardiac remodeling, and stimulate endogenous regeneration. While the current study focused on paracrine activity, implanted MSCs have 5 per well in 6-well plates for 24 h and then stimulated by 10 ng/ml PDGF for 48 h. Total MSC miRNA was isolated and enriched using a mirVana miRNA isolation kit. TaqMan MicroRNA Assays were then performed to examine the expression of mature hsa-miR-320b (Life Technologies Assay ID: MC13132), hsa-miR-23b (Assay ID:000400), hsa-miR-27b (Assay ID:000409), and hsa-miR-16-2 (Assay ID: 002171) in naïve human and PDGF-treated MSCs. Each sample was analyzed in triplicate. 10 ng of enriched small RNA was converted into cDNA and real-time PCR was performed using standard Taqman MicroRNA Assays protocol. The Taqman MicroRNA Assay for RNU44 (Assay ID:001094) was used to normalize the relative abundance of miRNA. Fold-changes were calculated using the 2 Ϫ
DD
Ct method, with samples from naïve human MSC being used as the calibrator. A-D: PDGF pretreatment for 48 h increased hsa-miR-16-2 expression but suppressed the expression of hsa-miR-23b, 27b, and 320b. *P Ͻ 0.05 vs. control. also been shown to phenotypically resemble cardiac myocytes (46) ; it would be interesting to examine the effects of PDGF on this differentiation-like process.
Besides the secretion of soluble protein factors, MSCs may also communicate with other cell types in the ischemic heart by cell-derived small circular membrane vesicles, called exosomes and microvesicles (29) . Shuttling of intracellular components, such as mRNAs, miRNAs, and proteins via secreted cell membrane vesicles, represents a novel mechanism of cell-to-cell communication (47) . Thus transfer of intracellular components from MSCs to other cell types, such as cardiomyocytes, fibroblasts, and cardiac progenitor cells, may reprogram cells in the ischemic myocardium to improve the outcome of acute or chronic heart injury. However, clinical trials have demonstrated that while effective, delivery of MSCs to ischemic myocardium resulted in only modest and short-lived benefits (1, 11) . Thus it is critical to elucidate the mechanisms by which MSCs mediate their therapeutic benefits to identify ways in which their functions can be optimized.
Platelet-derived growth factor (PDGF) is a potent mitogen of MSCs (26) , modulating MSC function via activation of PDGF receptor (PDGFR)-␣ and PDGFR␤ (45) . Upon stimulation, the receptors associate with a number of signaling molecules including MAPKs, JNK, PKB/Akt, and gene-regulating transcription factors such as c-Jun and STAT family members (15, 43) . Interestingly, PDGF-induced proliferation was prevented by pretreatment with a JNK inhibitor but not by inhibitors of p38 MAPK or ERK1/2 (26) . Overexpression of a dominantnegative form of c-Jun, a downstream transcription factor that is activated by JNK, inhibits PDGF-induced proliferation (55). These observations indicate that JNK signaling plays a key role in PDGF-induced proliferation and migration. In the current study, we also observed that PDGF (10 ng/ml) activated c-Jun in only 10 min. Preconditioning of MSCs with PDGF for 48 h significantly improved MSC-mediated cardioprotection in a mouse model of cardiac ischemia-reperfusion injury (Fig. 2) . It is possible that PDGF signaling pathways play a beneficial role in MSC-mediated cardioprotection via c-Jun dependent, transcriptional induction of paracrine factors (Fig. 6) .
In addition to increasing the release of protein factors, PDGF may also stimulate the release of exosomes and microvesicles that deliver miRNAs and mRNAs to cells in the ischemic region via horizontal transfer (54) . Such transfer of intracellular genetic material would 1) regulate the proliferation, differentiation, and cell-cycle reentry of resident cardiac progenitor cells, thus restraining tissue injury and leading to tissue self-repair (5); 2) suppress ischemic cardiomycyte injury and death; and 3) reprogram fibroblasts and epithelial cells to attenuate ventricular remodeling after ischemic injury (Fig. 6) . Indeed, we observed that PDGF modulated the expression of c-Jun-targeted miRNAs, and overexpression of miR-320b, a predicted c-Jun target, abolished the effects of PDGF in improving MSC therapeutic efficacy. Thus PDGF may improve MSC-mediated cardioprotection, at least in part, via downregulation of miR-320b.
Despite our intensive characterization, we failed to detect the paracrine factors suppressed by miR-320. Surprisingly,
Control miR
Control miR+ PDGF *^^* * *F ig. 5. Expression of angiogenic growth factors following PDGF treatment. MSCs were plated at 1 ϫ 10 5 per well in 6-well plates for 24 h before microRNA transfection. After transfection, cells were allowed to recover for 24 h and then treated with PDGF (10 ng/ml) for another 48 h. Supernatants were then collected from each group and analyzed using an angiogenesis array (A) and ELISA (B) assays. MSC expression of VEGF and stromal cell-derived factor-1 (SDF-1) was examined using RT-PCR (B). A, top: representative angiogenic array blots. A, bottom: qualified array signals as pixel densities. B, top: total amounts of VEGF, SDF-1 in the various supernatants and cell numbers at time of supernatant collection. Data are representative of at least 3 independent experiments. B, bottom: MSC expression of VEGF and SDF-1 (with control miR or miR-320 transfection) treated with PDGF. Results are means Ϯ SE; n ϭ 3/group. *P Ͻ 0.05 vs. control miR group; ٙ P Ͻ 0.05 vs. miR-320 group.
most paracrine factors we detected were found to be unchanged or be upregulated by miR-320 overexpression. IGFBP-1, -2, and -3, however, were found to be significantly unregulated following miR-320 overexpression. IGFBPs help to lengthen the half-life of circulating IGF-1 and may act to enhance or attenuate IGF-1 signaling (24) . A role for PDGF in IGF signaling has been previously suggested by demonstrating PDGF upregulated IGFBP-4 in fetal lung fibroblasts and other IGFs/IGFPs, following hypoxic/ischemic brain injury (4, 39) . Whether miR-320 alters PDGF-associated IGF-1 signaling by upregulation of IGFBPS in MSCs warrants future investigation. It is unlikely that residual PDGF in MSC preparations before infusion caused improved heart function, as observed in the PDGF and PDGF ϩ control miR groups, as the MSC-conferred protective effects were completely abolished in the PDGF ϩ miR-320 group. We also tested whether any molecules were released from MSCs during the PBS washing process. The PBS solution separated from MSCs via brief centrifugation was tested using the Langendorff model. No protective effects were observed in the isolated hearts receiving the PBS solution (data not shown), suggesting that the observed heart protection was from MSCs exclusively and not from PDGF contamination or any other biological molecules released into PBS during cell preparation before infusion.
Perspectives and Significance
MSCs hold great promise for treating ischemic heart diseases (2, 37) . Several groups have reported that intramyocar- For the protein array, n ϭ 2. miRNA, mircoRNA; IGFBP, insulin-like growth factor binding protein; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue inhibitor of matrix metalloproteinase. dial administration of MSCs reduced inflammation, fibrosis, infarct size, and ventricular remodeling, thus improving cardiac function (17, 18, 28, 44) . It is of critical importance to study the precise mechanisms underlying MSC therapeutic effects and use growth factors and molecular interventions to modify MSCs and optimize their ability to repair injured heart tissue. Further experiments, such as investigating the differentiation, long-term survival, microvesicle shedding, and paracrine signaling properties of PDGF-pretreated MSCs to ischemic heart may provide better insight into the mechanism of MSC-mediated cardioprotection and ways to maximize their potential for treating this worldwide-leading cause of mortality.
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